Date: 2015-01-02
Type of information: Validation of a production plant
Compound: new plant of the Grifols’ industrial complex in Los Angeles
Company: Grifols (Spain)
Therapeutic area:
Type agreement: validation of a production plant
Action mechanism:
Disease:
Details: * On January 2, 2015, Grifols, a leader in the production of plasma-derived medicines, has received approval from the FDA for its new plant for the purification of intravenous immunoglobulin (IVIG) 10%, the most important and widely consumed plasma protein, which the company markets under the Flebogamma® and Gamunex® brands.The new plant forms part of Grifols’ industrial complex in Los Angeles (United States) and represents an investment of 53 million euros. The plant has a total area of 9,000 m2 and a purification capacity of 17 million grams of immunoglobulin per year, increasing the manufacturing capacity for Gamunex®. The company expects the new plant to come on stream in 2015, as scheduled, and to lead to the creation of over 100 new jobs.
The facilities were designed by Grifols Engineering S.A., a Grifols company specializing in engineering pharmaceutical and biotechnology processes. The plant incorporates the very latest equipment, to ensure that the purification process for this plasma protein is characterized by the highest levels of safety, quality and efficacy. In addition, the plant has cutting edge technology to reduce the environmental impact of its activity by reducing the use of water and energy.
Financial terms:
Latest news:
